Clin Cancer Res: Long-term follow-up results of Venetog monotherapy for relapsed/refractory non-Hodgkin's lymphoma

Overexpression of the anti-apoptotic protein B-cell lymphoma /leukemia-2 (BCL-2) provides a survival advantage for malignant B-cells, and is involved in tumorigenesis, disease progression, and chemotherapy resistance of B-cell malignancies

Lymphoma Venetoclax (Venetoclax) is an oral selective BCL-2 inhibitor that has been approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).

In a phase 1 clinical trial of Venetog for relapsed/refractory NHL, the overall objective response rate (ORR) was as high as 44% .

A total of 106 patients received Venetog (in increasing doses from 200 mg to 1200 mg) monotherapy until the disease progressed or intolerable toxicity appeared

The treatment response of each subgroup

The treatment response of each subgroup

After a median follow-up of 38.

The median PFS for all patients was 5.

Duration of remission (A) and PFS (B) in patients with MCL and FL

Duration of remission (A) and PFS (B) in patients with MCL and FL

Hematological AEs of all grades are uncommon : neutropenia (19%), anemia (19%), and thrombocytopenia (17%).

Hematology AEs of all levels are uncommon

In summary, in the FL, MCL, WM, and MZL subgroups, Venetog monotherapy can achieve long-lasting remission (especially in patients with complete remission), and the safety is controllable

In the FL, MCL, WM, and MZL subgroups, Venetog monotherapy can achieve lasting remission (especially in patients with complete remission), and the safety is controllable in the FL, MCL, WM, and MZL subgroups , Venetog monotherapy can obtain lasting remission (especially in patients with complete remission), and the safety is controllable

Original source:

Original source:

Matthew S.

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

in this message